Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Jay Barth sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $13.59, for a total value of $67,950.00. Following the completion of the transaction, the insider now directly owns 69,184 shares in the company, valued at $940,210.56. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Amicus Therapeutics, Inc. (NASDAQ FOLD) traded up $0.03 during trading hours on Thursday, reaching $12.54. The company’s stock had a trading volume of 1,823,600 shares, compared to its average volume of 3,179,943. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $16.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The firm had revenue of $10.90 million for the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm’s quarterly revenue was up 419.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.33) EPS. analysts expect that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current year.
FOLD has been the topic of several recent analyst reports. Chardan Capital boosted their target price on Amicus Therapeutics from $12.50 to $17.50 and gave the stock a “buy” rating in a report on Thursday, August 10th. Leerink Swann reaffirmed a “buy” rating and set a $20.00 price objective (up previously from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Bank of America upped their price objective on Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, October 4th. BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Finally, Cowen reaffirmed a “buy” rating and set a $16.00 price objective on shares of Amicus Therapeutics in a report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.81.
Several hedge funds have recently bought and sold shares of the company. FMR LLC lifted its stake in shares of Amicus Therapeutics by 3.4% in the 2nd quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock valued at $215,876,000 after purchasing an additional 705,153 shares during the period. Perceptive Advisors LLC lifted its stake in shares of Amicus Therapeutics by 3.4% in the 3rd quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock valued at $269,760,000 after purchasing an additional 591,925 shares during the period. Redmile Group LLC lifted its stake in shares of Amicus Therapeutics by 5.9% in the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after purchasing an additional 668,080 shares during the period. Jennison Associates LLC lifted its stake in shares of Amicus Therapeutics by 9.4% in the 3rd quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock valued at $147,362,000 after purchasing an additional 838,267 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Amicus Therapeutics by 5.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after purchasing an additional 430,486 shares during the period.
TRADEMARK VIOLATION WARNING: “Jay Barth Sells 5,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock” was originally published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.thestockobserver.com/2017/12/07/jay-barth-sells-5000-shares-of-amicus-therapeutics-inc-fold-stock.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.